

VPA10988/101/002

CANIXIN DHPPi/L lyophilisate suspension for injection for dogs

Variation	Summary	Date
Vet - F.I.a.1 c)	VRA-S - Vet - F.I.a.1 c) - c) New manufacturer of material for which an assessment is required of viral safety and/or TSE risk - F.I.a.1 c) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - New manufacturer of material for which an assessment is required of viral safety and/or TSE risk	03/08/23
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	24/10/22